Download or read book Antipsychotic Drugs and Their Side Effects written by Thomas R.E. Barnes and published by Academic Press. This book was released on 2013-10-22 with total page 304 pages. Available in PDF, EPUB and Kindle. Book excerpt: In line with other volumes in the Neuroscience Perspectives Series, this volume covers the background, pharmacology, molecular biology, and biochemistry of antipsychotic drugs, together with an overview assessment of the therapeutic considerations. Over the past 40 years, the effectiveness of conventional neuroleptic agents for psychotic illness has been offset by a wide range of adverse side-effects, including motor side-effects like parkinsonism. Studies show that lowering doses may still produce the antipsychotic effect while lessening the risk of side-effects. As all available antispychotic drugs are able to block dopamine, specifically D2 receptors, doses below the threshold level for producing acute motor disorder can still be therapeutically effective. With the identification and characterization of multiple dopamine receptors, the possibility of more selective drugs with better side-effect potential has arisen. Other novel antipsychotic agents include D1 receptor blockers, partial dopamine agonists and non-dopamine drugs such as 5-HT receptor blockers, sigma receptor antagonists and NMDA receptor agonists. This volume reviews both the basic science of the conventional and atypical neuroleptics and their present and potential therapeutic use.
Download or read book Life Threatening Effects of Antipsychotic Drugs written by Peter Manu and published by Academic Press. This book was released on 2016-08-16 with total page 394 pages. Available in PDF, EPUB and Kindle. Book excerpt: Life-Threatening Effects of Antipsychotic Drugs describes in detail more than 20 life-threatening effects associated with antipsychotics, presents the best available data on their incidence and case fatality, and gives comprehensive advice on diagnosis, management and preventive strategies. In addition, the book discusses the benefit of antipsychotic medication in a range of therapeutic indications, and demonstrates the gain in life-expectancy associated with clozapine use in severe mental illness despite its serious, potentially life-threatening adverse effects. Covers cardiovascular, neurological, muscular, hematological, gastrointestinal, autonomic and metabolic effects Gives advice on risk factors, confounding diagnoses and measures to minimise seriousness Discusses clozapine rechallenge after each of its serious adverse reactions Makes suggestions for optimum management of somatic disease in those with severe mental illness, to improve life-expectancy Includes data on post-mortem considerations
Download or read book Antipsychotics and their Side Effects written by David M. Gardner and published by Cambridge University Press. This book was released on 2010-11-11 with total page 228 pages. Available in PDF, EPUB and Kindle. Book excerpt: With the remarkable expansion in the use of antipsychotics, concerns about their immediate, intermediate, and long-term adverse effects have intensified. Despite this, studies consistently show that monitoring of patients taking antipsychotics can be inadequate, haphazard, or worse. This book provides a comprehensive review of the adverse effects of this pharmacologically complex therapeutic class, covering all commonly used conventional and atypical agents. In the first section, each chapter provides background information about an adverse effect, reviews the evidence linking the effect to various antipsychotics, and provides specific detection and monitoring recommendations. The second section provides unique monitoring guides for each antipsychotic. The third section provides the clinician with a program to monitor patients over the long-term. By supporting rational treatment decisions and systematic adverse effect monitoring, Antipsychotics and Their Side Effects provides the clinician with the necessary information and tools for optimizing the safe and effective long-term use of antipsychotic drugs.
Download or read book A Guide to the Extrapyramidal Side Effects of Antipsychotic Drugs written by D. G. Cunningham Owens and published by Cambridge University Press. This book was released on 1999-03-11 with total page 370 pages. Available in PDF, EPUB and Kindle. Book excerpt: A very readable and well illustrated 1999 clinical guide to the common side effects of antipsychotic medication.
Download or read book Antipsychotic Long acting Injections written by Peter Haddad and published by Oxford University Press. This book was released on 2016-05-10 with total page 320 pages. Available in PDF, EPUB and Kindle. Book excerpt: Antipsychotic Long-acting Injections (LAIs) were introduced in the 1960s to improve treatment adherence in schizophrenia. Subsequently, first-generation antipsychotic LAIs became widely used in many countries. Since the initial publication of Antipsychotic Long-acting Injections in 2010, new trial data have been published on long-acting injection (LAI) preparations of the drugs Risperidone, Paliperidone, and Olanzapine. Furthermore, a new LAI preparation of the drug Aripiprazole has recently been approved for clinical use in the United States and is likely to be approved in Europe soon. The second edition of this successful book has been fully updated to include this new data, with reference to both observational studies and randomized controlled trials, as well as other new developments in the clinical use of antipsychotic LAIs. New chapters have been added covering the comparison between oral and injectable antipsychotics, Olanzapine LAI, Aripiprazole LAI, and the practicalities of organizing a specialized clinic for long-acting injectable antipsychotics. Existing chapters have also been thoroughly updated to take into account the most recently published research. Antipsychotic Long-acting Injections, Second edition brings together clinical and research findings on LAIs in a comprehensive volume, with chapters written by international experts.
Download or read book Current Antipsychotics written by Gerhard Gross and published by Springer. This book was released on 2014-12-14 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: Six decades after the serendipitous discovery of chlorpromazine as an antipsychotic and four decades after the launch of clozapine, the first atypical or second generation antipsychotic, psychopharmacology has arrived at an important crossroad. It is clear that pharmacological research and pharmaceutical development must now focus on complementary or even alternative mechanisms of action to address unmet medical needs, i.e. poorly treated domains of schizophrenia, improved acceptance by patients, better adherence to medication, safety in psychoses in demented patients, and avoiding cardiac and metabolic adverse effects. The first completely novel mechanisms evolving from our insights into the pathophysiology of psychotic disorders, especially the role of glutamatergic mechanisms in schizophrenia, are now under development, and further principles are on the horizon. This situation, in many respects similar to that when the initial second-generation antipsychotics became available, can be rewarding for all. Preclinical and clinical researchers now have the opportunity to confirm their hypotheses and the pharmaceutical industry may be able to develop really novel classes of therapeutics. When we were approached by the publishers of the Handbook of Experimental Pharmacology to prepare a new volume on antipsychotics, our intention was to capture both, the accumulated preclinical and clinical knowledge about current antipsychotics as well as prospects for new and potentially more specific antischizophrenia principles. These efforts should be based on the pathophysiology of the diseases and the affected neurotransmitter systems. Since preclinical research on antipsychotic compounds is only reliable when intimately linked through translational aspects to clinical results, we decided to include clinical science as well. It turned out that that this endeavor could not be covered by a single volume. We thank the editorial board and the publishers for supporting our decision to prepare two volumes: Current Antipsychotics and Novel Antischizophrenia Treatments. These topics cannot really be separated from one another and should be seen as a composite entity despite the somewhat arbitrary separation of contributions into two volumes. The continuing challenges of developing improved and safer antipsychotic medications remain of concern and are discussed in the first volume. The new opportunities for the field to develop and license adjunctive treatments for the negative symptoms and cognitive deficits that are treated inadequately by existing compounds have been incentivized recently and provide the focus for the second volume. We hope these collective contributions will facilitate the development of improved treatments for the full range of symptomatology seen in the group of schizophrenias and other major psychotic disorders. Gerhard Gross, Ludwigshafen, Germany Mark A. Geyer, La Jolla, CA This volume will try to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters will also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. Non-schizophrenia indications will be covered to some extent, but not exhaustively.
Download or read book Physical Health and Schizophrenia written by David J. Castle and published by Oxford University Press. This book was released on 2017-09-08 with total page 136 pages. Available in PDF, EPUB and Kindle. Book excerpt: In comparison to the general population, people with schizophrenia and related disorders have poorer physical health and increased mortality. Whilst it is recognised that serious mental illnesses such as schizophrenia carry a reduced life expectancy, it is often assumed that suicide is the main cause of this disparity. In actuality, suicide accounts for no more than a third of the early mortality associated with schizophrenia: the vast majority is due to cardiovascular factors Physical Health and Schizophrenia offers a user-friendly guide to the physical health problems associated with schizophrenia and a clear overview of strategies and interventions to tackle these issues. Spanning eight chapters this resource covers the essential topics in a practical and easy-to-read format to suit the needs of busy clinicians. It also includes an appendix designed specifically for patients and carers, with practical tips on how to be actively involved in monitoring and managing physical health problems. Part of the Oxford Psychiatry Library series, Physical Health and Schizophrenia offers readers a fully up-to-date and valuable insight into this complex issue. With helpful key points at the start of each chapter and a clear layout, this is an essential resource for busy clinicians and researchers in any mental health field as well as those working in primary care.
Download or read book First Generation Versus Second Generation Antipsychotics in Adults Comparative Effectiveness written by U. S. Department of Health and Human Services and published by Createspace Independent Pub. This book was released on 2013-03-24 with total page 570 pages. Available in PDF, EPUB and Kindle. Book excerpt: Antipsychotic medications are used to treat and manage symptoms for several psychiatric disorders and are commonly categorized into two classes. First-generation antipsychotics (FGAs), also known as “typical antipsychotics,” were developed in the 1950s. Second-generation antipsychotics (SGAs), also known as “atypical antipsychotics,” emerged in the 1980s. To date, FGAs have been classified according to their chemical structure, which includes serotonin-dopamine antagonists and multiacting receptor-targeted antipsychotics, whereas SGAs have been categorized according to their pharmacological properties as dopamine partial agonists. There is ongoing research testing the proposed mechanisms of action within each class with respect to the neurobiology of different psychiatric disorders. According to findings from the 2004–05 Medical Expenditure Panel Survey, an estimated 2 million adult patients in the U.S. were prescribed an antipsychotic medication, three quarters of whom were taking an SGA. In 2003, an estimated $2.82 billion were spent in the country on these medications, with SGAs accounting for 93% of this expenditure. Today, 20 FGAs and SGAs are commercially available in the U.S. and approved by the FDA. Individuals taking antipsychotics may stop taking their medication for a number of reasons, including adverse events (AEs) and a lack of improvement in their symptoms. As a result, ongoing evaluations of drug efficacy and models of patient decisionmaking are essential. This Review provides a comprehensive synthesis of the evidence examining the benefits and harms associated with the use of FDA-approved FGAs and SGAs. This CER focuses on comparisons of individual medications rather than drug classes. This topic is important and timely, given the ongoing debate about the comparative benefits and harms of FGAs and SGAs. The focus of this report complements other recent reviews investigating different SGAs, the off-label use of antipsychotics, and FGAs versus SGAs in the pediatric population. The focus of this report is adults age 18 to 64 years with schizophrenia, schizophrenia-related psychoses, and bipolar disorder. The following Key Questions were investigated in the report: 1. For adults (age 18 to 64 years) with schizophrenia, schizophrenia-related psychoses, or bipolar disorder, what are the comparative efficacy and effectiveness of FGAs versus SGAs for improving core illness symptoms? 2. For adults (age 18 to 64 years) with schizophrenia, schizophrenia-related psychoses, or bipolar disorder, what is the comparative effectiveness of FGAs versus SGAs for improving functional outcomes and decreasing health care system utilization? 3. For adults (age 18 to 64 years) with schizophrenia, schizophrenia-related psychoses, or bipolar disorder, do FGAs and SGAs differ in medication-associated AEs and safety? 4. For adults (age 18 to 64 years) with schizophrenia, schizophrenia-related psychoses, or bipolar disorder, what is the comparative effectiveness of FGAs versus SGAs for the following other outcomes: Relapse and remission rates, Medication adherence and persistent use, Patient insight into illness, Health-related quality of life, Patient satisfaction, Comorbidity: endpoints of victimization, homelessness, and substance abuse, Patient-reported outcomes, Ability to obtain and retain employment and succeed in job duties, Concomitant use of other medications, especially those used to treat EPS, and Patient preferences. 5. For adults (age 18 to 64 years) with schizophrenia, schizophrenia-related psychoses, or bipolar disorder, what are the comparative effectiveness and risks of FGAs versus SGAs in subgroups defined by the following variables? Disorder subtypes, Sex, Age group (18–35 years, 36–54 years, and 55–64 years), Race, Comorbidities, Drug dosage, Follow up period, Treatment of a first episode versus treatment in the context of previous episodes (previous exposure to antipsychotics), and Treatment resistance.
Download or read book Pharmacological Treatment of Mental Disorders in Primary Health Care written by World Health Organization and published by World Health Organization. This book was released on 2009 with total page 80 pages. Available in PDF, EPUB and Kindle. Book excerpt: This manual attempts to provide simple, adequate and evidence-based information to health care professionals in primary health care especially in low- and middle-income countries to be able to provide pharmacological treatment to persons with mental disorders. The manual contains basic principles of prescribing followed by chapters on medicines used in psychotic disorders; depressive disorders; bipolar disorders; generalized anxiety and sleep disorders; obsessive compulsive disorders and panic attacks; and alcohol and opioid dependence. The annexes provide information on evidence retrieval, assessment and synthesis and the peer view process.
Download or read book Mental Disorders in Primary Care written by Andre F. Carvalho and published by Oxford University Press. This book was released on 2017 with total page 385 pages. Available in PDF, EPUB and Kindle. Book excerpt: An invaluable guide to psychiatric presentation, diagnosis and treatment in a primary care setting.
Download or read book First Episode Psychosis written by Katherine J. Aitchison and published by CRC Press. This book was released on 2022-03-26 with total page 152 pages. Available in PDF, EPUB and Kindle. Book excerpt: The new edition of this popular handbook has been thoroughly updated to include the latest data concerning treatment of first-episode patients. Drawing from their experience, the authors discuss the presentation and assessment of the first psychotic episode and review the appropriate use of antipsychotic agents and psychosocial approaches in effective management. This is an authoritative text written by a team of highly respected authors for psychiatrists, neurologists, primary care practitioners and health care professional working in psychiatry. Drawing from their experience, the presentation and assessment of the first psychotic episode are discussed, details regarding antipsychotic drugs and their appropriate use are reviewed and psychosocial approaches are examined. The resulting book offers a concise and valuable guide to those wishing to review the latest proposals for the treatment of first-episode psychosis supported by up-to-date references, in a single publication.
Download or read book Psychotic Disorders written by Oliver Freudenreich and published by Springer Nature. This book was released on 2019-12-04 with total page 479 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book provides clear and concise guidance for clinicians when they encounter a patient with psychosis, starting with the medical work-up to arrive at a diagnosis and ending with the comprehensive care for patients with established schizophrenia. It covers the optimal use of medications (emphasizing safe use) but also addresses other treatment approaches (psychological treatments, rehabilitation) and the larger societal context of care, including how to work effectively in complex systems. It uniquely condenses the literature into teaching points without simplifying too much, effectively serving as a learning tool for trainees and professionals. For this second edition, the book was extensively updated and its content expanded, with new figures as well. Each chapter begins with an initial summary and includes Tips and Key Points in text boxes. Each chapter also includes links to external websites and additional readings. The book contains clinical and practical wisdom for clinicians who are treating real patients at the front lines, setting it apart from all other texts. Psychotic Disorders is an excellent resource for medical students, early career professionals such as trainees and fellows, and related clinicians seeking additional training and resources, including those in psychiatry, psychology, neurology, and all others.
Download or read book Antipsychotic Drugs written by Thomas L. Schwartz and published by Nova Science Publishers. This book was released on 2013 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: Since the mid-1990s, a revolution in regards to prescribing antipsychotics has taken place. Once utilized only for schizophrenia, the newer, second generation antipsychotics have now been approved for the treatment of bipolar disorders, depressive disorders, and autism spectrum disorders. They are often utilised elsewhere for the treatment of anxiety disorders, sleep disorders, and to calm agitated patients when dangerous behaviours occur. Prescription rates have soared making them some of the most advertised, prescribed and profitable drugs on the market. This book was developed with input of international authors of varying backgrounds to review the history and development of these agents and to focus on the utilization of these drugs in various disorders, age groups, and clinical situations.
Download or read book Drug Induced Movement Disorders written by Stewart Factor and published by John Wiley & Sons. This book was released on 2008-04-15 with total page 480 pages. Available in PDF, EPUB and Kindle. Book excerpt: The second revised edition of this text will update and present current state of the art clinical approaches to this subject. This book will continue to be the source text of information on drug-induced movement disorders authored and edited by the pioneers in the field. It will be an invaluable addition to the library of any neurologist.
Download or read book Schatzberg s Manual of Clinical Psychopharmacology Tenth Edition written by Charles DeBattista, D.M.H., M.D. and published by American Psychiatric Pub. This book was released on 2024-04-05 with total page 868 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia written by American Psychiatric Association and published by American Psychiatric Pub. This book was released on 2016 with total page 220 pages. Available in PDF, EPUB and Kindle. Book excerpt: The guideline offers clear, concise, and actionable recommendation statements to help clinicians to incorporate recommendations into clinical practice, with the goal of improving quality of care. Each recommendation is given a rating that reflects the level of confidence that potential benefits of an intervention outweigh potential harms.
Download or read book The Maudsley Prescribing Guidelines in Psychiatry written by David M. Taylor and published by John Wiley & Sons. This book was released on 2018-07-16 with total page 878 pages. Available in PDF, EPUB and Kindle. Book excerpt: The revised 13th edition of the essential reference for the prescribing of drugs for patients with mental health disorders The revised and updated 13th edition of The Maudsley Prescribing Guidelines in Psychiatry provides up-to-date information, expert guidance on prescribing practice in mental health, including drug choice, treatment of adverse effects and how to augment or switch medications. The text covers a wide range of topics including pharmacological interventions for schizophrenia, bipolar disorder, depression and anxiety, and many other less common conditions. There is advice on prescribing in children and adolescents, in substance misuse and in special patient groups. This world-renowned guide has been written in concise terms by an expert team of psychiatrists and specialist pharmacists. The Guidelines help with complex prescribing problems and include information on prescribing psychotropic medications outside their licensed indications as well as potential interactions with other medications and substances such as alcohol, tobacco and caffeine. In addition, each of the book’s 165 sections features a full reference list so that evidence on which guidance is based can be readily accessed. This important text: Is the world’s leading clinical resource for evidence-based prescribing in day-to-day clinical practice and for formulating prescribing policy Includes referenced information on topics such as transferring from one medication to another, prescribing psychotropic medications during pregnancy or breastfeeding, and treating patients with comorbid physical conditions, including impaired renal or hepatic function. Presents guidance on complex clinical problems that may not be encountered routinely Written for psychiatrists, neuropharmacologists, pharmacists and clinical psychologists as well as nurses and medical trainees, The Maudsley Prescribing Guidelines in Psychiatry are the established reference source for ensuring the safe and effective use of medications for patients presenting with mental health problems.
